metabolic dysfunction–associated steatotic liver disease

Overview

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), is a chronic liver disease defined by hepatic fat accumulation (steatosis) arising in the setting of metabolic dysfunction—such as obesity, insulin resistance, type 2 diabetes, hypertension, and dyslipidemia—in the absence of significant alcohol intake or other competing causes of liver injury. It is among the most common chronic liver diseases worldwide and spans a histological continuum from simple steatosis to metabolic dysfunction–associated steatohepatitis (MASH), the inflammatory subtype that can progress to hepatic fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related death. As the hepatic expression of systemic metabolic derangement, MASLD is closely tied to cardiovascular disease and type 2 diabetes, and MASH has become a leading indication for liver transplantation.

Its pathogenesis is multifactorial, driven by dysregulated lipid metabolism, insulin resistance, oxidative stress, chronic low-grade inflammation, and perturbation of the gut microbiota–bile acid (gut–liver) axis. Excess hepatic lipid, together with impaired fatty acid oxidation, promotes lipotoxic hepatocellular injury, activation of inflammatory signaling, and fibrogenesis in which hepatic stellate cells and mediators such as fibroblast activation protein (FAP) participate; FAP additionally modulates circulating substrates including fibroblast growth factor 21 (FGF21). Peroxisome proliferator-activated receptor alpha (PPARα) and related regulators of lipid handling are central to disease biology and are targets of therapeutic interest. Clinically, MASLD shows marked heterogeneity across age, sex, and racial and ethnic groups, and non-invasive tests are increasingly used to identify MASH and stratify the risk of progression, while metabolic risk factors and MASLD have also been linked to extrahepatic outcomes such as cognitive decline.

Recent Publications Summary

Recent publications on metabolic dysfunction–associated steatotic liver disease (MASLD) have focused on its heterogeneity, extrahepatic risk, and therapeutic modulation across preclinical, clinical, and population-based settings. A multi-omics genetic study identified three polygenic MASLD subtypes—reflecting hepatic lipid retention, hepatic lipid synthesis, and systemic lipid metabolism—that were associated with distinct risk profiles across 22 incident diseases in UK Biobank participants and were further explored with proteomic and Mendelian randomization analyses to implicate protein-mediated mechanisms 42580475Aug. In parallel, a retrospective cohort study is evaluating whether MASLD and metabolic dysfunction-associated steatohepatitis (MASH) are associated with incident mild cognitive impairment, vascular dementia, and Alzheimer disease in adults with metabolic risk factors 42424274Jul, while another real-world study examined MASH progression to cirrhosis, decompensation, and mortality and the utility of non-invasive tests for detection and risk stratification 42319114Jun.

Several studies addressed MASLD pathobiology through the gut-liver axis and lipid-handling pathways. An oral nanofibrous porous microsphere system based on quaternized chitosan and whey protein improved murine MASLD, lowering ALT, AST, hepatic triglycerides, hepatic cholesterol, and NAS score, while reshaping gut microbiota, modulating bile acid metabolism, and preserving intestinal barrier integrity through reactivation of hepatic FXR-SHP signaling 42489146Jul. Mechanistic work also examined fibroblast activation protein and its downstream substrates FGF21 and α2-antiplasmin in MASLD 42233208Jun, as well as the platelet-activating factor pathway in women with obesity-associated MASLD by assessing hepatic PAF receptor expression and circulating Lp-PLA2 across disease stages 41885053Mar.

Other publications evaluated nutrition, lifestyle, and natural product interventions. Higher Mediterranean diet adherence was associated with lower odds of MASLD in Greek adults, with risk estimated using non-invasive tools such as the Liver Fat Score and NASH-ION 41967401Apr. A study in older adults in China assessed physical activity level and type in relation to non-alcoholic fatty liver disease risk using the Physical Activity Scale for the Elderly. Experimental studies reported MASLD improvement with Pueraria montana var. lobata extract, which was linked to increased mitochondrial β-oxidation and mitochondrial-peroxisome contact 41947488Apr, and with active components of the Danshen-Shanzha herb pair, which were proposed to protect against MASLD by synergistically promoting fatty acid oxidation via PPARα, Plin-5, and Plin-2 41690426Feb. Untargeted metabolomics also suggested that Swertia mussotii ameliorated diet-induced fatty liver disease by restoring disrupted metabolic pathways, especially the TCA cycle and amino acid metabolism, and by activating the SIRT1/AMPK axis 42108548May.

Pediatric and obesity-focused studies further emphasized MASLD risk stratification and clinical detection. In children and adolescents with obesity, a parsimonious prediction model using age, sex, BMI SDS, and waist circumference was developed to identify MASLD risk and track worsening steatosis-associated metabolic markers 42223658Jun. A randomized controlled study is evaluating lactoferrin in obese children and adolescents with metabolic dysfunction-associated steatotic liver disease 41811599Mar. Broader reviews and clinical discussions also highlighted the close relationship between obesity, dyslipidemia, and MASLD, including progression to MASH over time 42250074Jun, and a survey-based study in people with type 2 diabetes underscored racial and ethnic differences among those at risk for MASLD and related complications 42296541Jun.

What Changes, What Holds

1. Genetic subtypes reveal that MASLD is not one disease but several biologically distinct risk states
NEW DIRECTION Polygenic stratification adds a layer of heterogeneity to the baseline account: beyond shared metabolic dysfunction, MASLD may be separable into hepatic lipid retention, hepatic lipid synthesis, and systemic lipid metabolism programs with different downstream disease associations 42580475Aug. That does not displace the established pathogenesis, but it does suggest that risk prediction and prevention may need subtype-specific rather than one-size-fits-all approaches, with protein-mediated mechanisms as plausible mediators.

2. Gut-liver signaling and lipid-handling pathways remain actionable mechanistic targets in MASLD
REINFORCES The nanofibrous formulation, FAP-linked substrate work, and platelet-activating factor data all fit the existing model that MASLD is driven and modified by lipid dysregulation, inflammatory signaling, and gut-liver axis perturbation 42489146Jul42233208Jun. What changes is not the core biology but the strength of support for specific nodes that may be therapeutically tractable, especially FXR-SHP signaling, FAP-associated pathways, and PAF signaling in obesity-associated disease.

3. Diet, activity, and natural products may modify MASLD, but the evidence still looks like risk association or preclinical support rather than a settled treatment effect
NEW DIRECTION Mediterranean diet adherence and physical activity reinforce lifestyle relevance, while the botanical and metabolomic studies point to candidate mechanisms through fatty acid oxidation, mitochondrial function, and AMPK/PPARα signaling 41967401Apr. None of this overturns the baseline; instead it broadens the intervention space beyond conventional metabolic management. The main unresolved issue is translation: these findings suggest modifiability, but not yet durable clinical efficacy.

4. Risk stratification is becoming more personalized across pediatric and diabetes settings, but the established need for noninvasive detection is unchanged
REINFORCES Prediction models in children with obesity, the lactoferrin trial, and the diabetes-focused disparities work all sit within the Overview’s existing emphasis on heterogeneous clinical expression and non-invasive stratification 42223658Jun41811599Mar42296541Jun. The real-world progression study similarly sharpens the utility of non-invasive tests for identifying advanced disease 42319114Jun. Together they reinforce, rather than revise, the need to detect progression earlier and to tailor assessment by age, metabolic burden, and ancestry.

Overview update candidates: polygenic MASLD subtypes with distinct disease-risk profiles; specific mechanistic links involving FXR-SHP; FAP-associated substrates; and PAF signaling; lifestyle and natural-product associations as potential modifiers; pediatric prediction modeling and real-world non-invasive risk stratification.